Gemfibrozil
Class
Hypolipidemic agents
Subclass
PPARα agonists
Substance name
Gemfibrozil
Brand names
Lopid®
Common formulations
Film-coated tablet
Dosage and administration
Adults patients
Familial combined hyperlipidemia
Familial hypertriglyceridemia
Mixed hyperlipidemia
Other off-label uses
Indications for use
Labeled indications
Adults
Off-label indications
Adults
Safety risks
Contraindications
Hypersensitivity to gemfibrozil or its components
Gallbladder disease
Hepatic impairment
Concomitant use of dasabuvir
Concomitant use of repaglinide
Concomitant use of selexipag
Concomitant use of simvastatin
Warnings and precautions
Anemia, decreased WBC count, decreased platelet count
Bleeding
Carcinogenesis
Cardiovascular mortality
Gallstones
Increased liver enzymes
Myositis
Rhabdomyolysis
Seizure
Specific populations
Renal impairment
CrCl ≥ 60 mL/min
CrCl 30-60 mL/min
CrCl < 30 mL/min
Renal replacement therapy
Any modality
Hepatic impairment
Any severity
Pregnancy and breastfeeding
Pregnancy
All trimesters • Australia Category: B3
Breastfeeding
Do not use during breastfeeding.
Unknown amount excreted in breastmilk.
Unknown drug levels in breastfed infants.
Adverse reactions
Very common > 10%
Common 1-10%
Uncommon < 1%
Unknown frequency
Interactions
Drug(s)
Check Interactions
Reset
What did you think about this content?
Sign up for free to access the full drug resource